KMDA Key Statistics, Chart & Performance
The current stock price of KMDA is 8.15 USD. In the past month the price increased by 17.21%. In the past year, price increased by 7.15%.
KMDA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to KMDA. When comparing the yearly performance of all stocks, KMDA is one of the better performing stocks in the market, outperforming 76.09% of all stocks.
KMDA Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to KMDA. While KMDA has a great profitability rating, there are some minor concerns on its financial health.
KMDA Financial Highlights
Over the last trailing twelve months KMDA reported a non-GAAP Earnings per Share(EPS) of 0.36. The EPS increased by 28.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 11.7% | ||
| ROA | 5.42% | ||
| ROE | 7.72% | ||
| Debt/Equity | 0.04 |
KMDA Forecast & Estimates
9 analysts have analysed KMDA and the average price target is 13.26 USD. This implies a price increase of 62.7% is expected in the next year compared to the current price of 8.15.
For the next year, analysts expect an EPS growth of 44.17% and a revenue growth 12.37% for KMDA
KMDA Ownership
KMDA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.9 | 399.25B | ||
| AMGN | AMGEN INC | 15.56 | 183.26B | ||
| GILD | GILEAD SCIENCES INC | 17.55 | 178.34B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.76 | 117.85B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.15 | 79.99B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 685.96 | 46.22B | ||
| INSM | INSMED INC | N/A | 33.46B | ||
| NTRA | NATERA INC | N/A | 31.29B | ||
| BIIB | BIOGEN INC | 10.59 | 26.01B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.09 | 20.56B | ||
| INCY | INCYTE CORP | 15.7 | 19.79B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.46B |
Related stock screener links
About KMDA
Company Profile
Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. The firm uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Company Info
KAMADA LTD
2 Holtzman St., Science Park
Rehovot 7670402 IL
CEO: Amir London
Employees: 374
Phone: 97289406472
KAMADA LTD / KMDA FAQ
Can you describe the business of KAMADA LTD?
Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. The firm uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
What is the current price of KMDA stock?
The current stock price of KMDA is 8.15 USD. The price decreased by -1.09% in the last trading session.
What is the dividend status of KAMADA LTD?
KAMADA LTD (KMDA) has a dividend yield of 2.4%. The yearly dividend amount is currently 0.
How is the ChartMill rating for KAMADA LTD?
KMDA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Which stock exchange lists KMDA stock?
KMDA stock is listed on the Nasdaq exchange.
Can you provide the market cap for KAMADA LTD?
KAMADA LTD (KMDA) has a market capitalization of 470.09M USD. This makes KMDA a Small Cap stock.
What is the ownership structure of KAMADA LTD (KMDA)?
You can find the ownership structure of KAMADA LTD (KMDA) on the Ownership tab.